Syngene Q4 FY25: ₹1,018cr revenue, FY26 growth guide

What Syngene reported and why it drew attention

Syngene International Ltd announced results for the quarter ended March 2025 on April 23, 2025. The company reported revenue from operations of ₹1,018 crore, crossing the ₹1,000 crore quarterly threshold for the first time, as referenced in the earnings commentary. While revenue rose year-on-year, investors focused on profitability trends and the management’s cautious tone on the year ahead. That combination set up a sharp market reaction in the next session.

The company’s Board also recommended a final dividend for FY25, which brought the annual shareholder payout into focus alongside earnings. Separately, the dataset snippet included two “revenue earned” figures for Syngene of ₹917 and ₹874 (the unit was not specified in the snippet). The rest of the reported financials in the material were presented in ₹ crore terms.

Q4 FY25 revenue and operating performance

For Q4 FY25 (January to March 2025), Syngene reported revenue from operations of ₹1,018 crore, up 11% year-on-year from ₹916.9 crore. One report noted that this revenue number missed street expectations of ₹1,066 crore. Total income for the quarter was also reported at ₹1,037 crore, up from ₹933 crore a year earlier.

Operationally, EBITDA for the quarter was reported at ₹343.6 crore, a year-on-year increase of 8.4% from ₹316 crore. EBITDA also came in below the cited street expectation of ₹350 crore. The EBITDA margin was reported at 33.8% for the quarter, compared with 34.4% in Q4 FY24, and above an estimation cited at 33%. In the management commentary, operating EBITDA margin for the quarter was described at 34% versus 35% a year earlier.

Net profit print: differing references and the “exceptional items” context

Syngene’s consolidated net profit for Q4 FY25 was reported at ₹183.3 crore. One report described this as 2.8% year-on-year growth. Another report said consolidated net profit declined 3% year-on-year to ₹183 crore from ₹189 crore in the same period last year.

In the earnings commentary, the company also referenced “reported PAT before exceptional items” for the quarter, stating it decreased 3% year-on-year to ₹183 crore. The presence of “before exceptional items” language and rounding differences helps explain why multiple summaries in the provided material frame the year-on-year movement differently while pointing to the same ₹183 crore area for quarterly profit.

Cost, depreciation, and tax-rate details cited for the quarter

The earnings commentary included several line-item metrics for Q4 FY25. Raw materials cost was stated at 23.1% of revenue, with the note that Q4 FY24 had benefited from a lower base due to reversal of inventory provisions of prior quarters. Depreciation charges were described as decreasing 4% year-on-year, aided by a change in accounting estimate in Q1 FY25 and partly offset by new facilities coming onstream.

Operating profit (EBIT) was stated to have increased 15% versus last year, supported by higher revenue and lower depreciation. Other income was said to have increased 18% due to higher interest from deposits and gains on sale of short-term investments. Interest expense rose 24% compared to the previous year, attributed to the finance component of leases. The underlying effective tax rate for the quarter was cited at around 23.8% versus 20.8% in Q4 FY24.

FY25 numbers: revenue, margins, and profit

For the full fiscal year, one report stated Syngene’s total income increased to ₹3,714 crore from ₹3,579 crore in FY24. The same report said net profit for FY25 was ₹496 crore, down from ₹510 crore in FY24.

In the management commentary, reported revenue from operations for FY25 grew 4% year-on-year and 2% in constant currency, in line with guidance updated in January 2025. Operating EBITDA margins for the year were cited at 28.6%, in line with guidance of “high-20s.” EBIT was stated to be flat at ₹681 crore. Reported PAT before exceptional items for the year was stated to be down 8% to ₹475 crore, while the company added that underlying PAT increased 1% year-on-year after adjusting for specified one-offs.

Business mix references: small-molecule CDMO share

The provided material highlighted a shift in the contribution of small-molecule CDMO. Management commentary stated small-molecule CDMO contributed 12% in FY25, down from 16% in the prior year. The commentary also referenced that within the year, step-backs related to client clinical programs and reduced annual commercial manufacturing volume demand led to a net year-on-year revenue decline of 24% for that portion of activity.

It also said growth was driven by both research and CDMO businesses, while being partially offset by a decline in the small-molecule CDM business. Raw material costs as a percentage of revenue improved in FY25 compared to FY24, attributed to business mix changes and improved yield in biologics.

Dividend: recommendation date and amount

Syngene’s Board recommended a final dividend of ₹1.25 per equity share for FY25, subject to shareholders’ approval. The dataset snippet also stated that Syngene declared a dividend of ₹1.25 on June 27, 2025. Both references point to the same per-share payout amount, with the formal approval step noted in the results coverage.

Stock reaction and the cited reasons

Shares of Syngene fell over 10% on Thursday, April 24, 2025, following the earnings announcement and the management’s conservative outlook commentary. The reports linked the move to the weaker-than-expected topline versus street expectations and guidance that was described as significantly below expectations.

Separately, the provided trading snapshot showed Syngene International Ltd (NSE: SYNGENE | BSE: 539268) at ₹667.60, up ₹8.45 (1.28%), with a stated 30.50% fall from its 52-week high. The snapshot also showed combined NSE+BSE volume of 485.2K, timestamped 14 Aug, 2025 at 3:31 PM IST.

FY26 commentary: growth, margins, and profit expectation

CEO Peter Bains said he anticipates revenue growth in the early teens across all service areas. But he added that, adjusted for “inventory balancing in large molecule commercial manufacturing at client level,” reported revenue growth is likely to be in the mid-single digits.

CFO Deepak Jain said EBITDA margin may moderate from current levels to the mid-twenties and that there may be a year-on-year decline in profit after tax. A brokerage note cited by CNBC-Awaaz said guidance implied mid-single-digit revenue growth for FY26, compared with consensus building for 15% INR revenue growth, and suggested 8-10% cuts to FY26 revenue estimates.

Key numbers table (as reported in the material)

Why the update matters for investors

The Q4 print showed Syngene scaling quarterly revenue above ₹1,000 crore, but the quarter also included a revenue miss versus a cited street expectation and slightly softer margins year-on-year. The management’s references to inventory balancing at the client level in large molecule commercial manufacturing and the possibility of mid-twenties EBITDA margins helped explain why the market reacted strongly despite year-on-year revenue growth.

The FY25 picture in the provided material points to modest growth in reported revenue from operations, steady EBIT at ₹681 crore, and a decline in reported PAT before exceptional items to ₹475 crore. Investors tracking Syngene’s mix are likely to focus on how the smaller contribution from small-molecule CDMO and the cited step-backs in certain client programs interact with the company’s broader research and CDMO growth drivers.

Conclusion

Syngene’s Q4 FY25 results combined double-digit year-on-year revenue growth with a modest margin softening and mixed profit descriptors around the ₹183 crore level. The stock’s sharp decline after results was tied to conservative FY26 commentary on reported growth, margin moderation to the mid-twenties, and a possible year-on-year decline in profit after tax. The next key marker in the public record, based on the provided material, is shareholder consideration of the ₹1.25 final dividend recommended for FY25.